Nitin Jain, MD
Patients with IGHV
-mutated chronic lymphocytic leukemia (CLL) had high rates of minimal residual disease-negative (MRD–) status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab (GA101; iFCG).
More than half of patients (57%) required a dose reduction of FC and 18% of patients required a dose reduction of ibrutinib because of AEs. Just over one-third of patients (35%) required a treatment delay of 2 or more weeks due to AEs.
Jain N, Thompson PA, Burger JA, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). J Clin Oncol 35, 2017 (suppl; abstr 7522).
... to read the full story